- ICH GCP
- Registro de ensaios clínicos dos EUA
- Ensaio Clínico NCT00769808
Technolas 217z Laser With Zyoptix Aspheric Algorithm Used for the LASIK Treatment of Myopia and Myopic Astigmatism.
24 de agosto de 2020 atualizado por: Bausch & Lomb Incorporated
A Prospective Trial to Evaluate the Safety and Effectiveness of the Bausch & Lomb Technolas® 217z Laser With Zyoptix® Aspheric Algorithm When Used for the LASIK Treatment of Myopia and Myopic Astigmatism
The purpose of this study is to evaluate the safety and effectiveness of the Bausch & Lomb Technolas 217z laser with the investigational Zyoptix Aspheric Algorithm when used for LASIK treatment of myopia and myopic astigmatism.
Visão geral do estudo
Status
Concluído
Condições
Intervenção / Tratamento
Tipo de estudo
Intervencional
Inscrição (Real)
72
Estágio
- Não aplicável
Contactos e Locais
Esta seção fornece os detalhes de contato para aqueles que conduzem o estudo e informações sobre onde este estudo está sendo realizado.
Locais de estudo
-
-
Ontario
-
Toronto, Ontario, Canadá, M5X1C8
- Lasik MD, 130 King Street
-
-
Critérios de participação
Os pesquisadores procuram pessoas que se encaixem em uma determinada descrição, chamada de critérios de elegibilidade. Alguns exemplos desses critérios são a condição geral de saúde de uma pessoa ou tratamentos anteriores.
Critérios de elegibilidade
Idades elegíveis para estudo
18 anos e mais velhos (Adulto, Adulto mais velho)
Aceita Voluntários Saudáveis
Não
Gêneros Elegíveis para o Estudo
Tudo
Descrição
Inclusion Criteria:
- Subjects who were of legal age (at least 18) and had full legal capacity to volunteer.
- Subjects must be willing to have both eyes treated with the laser.
- Subjects must have up to -12.00D of absolute spherical myopia (not spherical equivalent) with up to -6.00D of refractive astigmatism, with a spherical equivalent up to -15.00D as measured by manifest subjective refraction.
- Subjects who had less than 0.75 D of difference in the preoperative manifest spherical equivalent and cycloplegic spherical equivalent subjective refractions.
(Manifest subjective refractions adjusted for optical infinity were used.)
- High contrast, manifest best spectacle-corrected distance logMAR visual acuity correctable to at least 0.3 in both eyes, and must not differ between eyes by more than 1 line (5 letters).
- Contact lens wearers must have 2 Orbscan measurements and 2 manifest subjective refractions taken preoperatively at least 1 week apart.
- Contact lens wearers must have gas permeable lenses discontinued for at least 3 weeks and soft lenses discontinued for at least 2 weeks prior to the preoperative evaluation.
Exclusion
- Subjects with uncorrected visual acuity better than 20/40 (Snellen) or 0.3 logMAR
- Subjects who were immuno-compromised or had a diagnosis of connective tissue disease, clinically significant atopic disease, diabetes, autoimmune diseases and other acute or chronic illnesses that increased the risk to the subject or could have confounded the outcomes of this study.
- Subjects with uncontrolled glaucoma or glaucoma who were under treatment in the study eye or with ocular hypertension.
- Subjects who demonstrated evidence of retinal vascular disease.
- Subjects who have an ocular muscle disorder including strabismus or nystagmus, or other disorders that affected fixation.
- Subjects who were at risk for angle closure or who had a potentially occludable angle, as evidenced by a shallow anterior chamber on slit lamp exam, confirmed by gonioscopy as deemed necessary by the study Investigator.
- Subjects who had undergone previous intraocular or corneal surgery of any kind, including any type of excimer laser surgery for either refractive or therapeutic purposes.
- Subjects who were taking systemic medications likely to affect wound healing such as corticosteroids or anti-metabolites or any other medications that may increase the risk to the subject or confound the outcomes of this study.
- Subjects for whom the combination of their preoperative corneal thickness and the planned operative parameters for the LASIK procedure could have resulted in less than 250 microns of remaining posterior corneal thickness below the flap postoperatively.
Plano de estudo
Esta seção fornece detalhes do plano de estudo, incluindo como o estudo é projetado e o que o estudo está medindo.
Como o estudo é projetado?
Detalhes do projeto
- Finalidade Principal: Tratamento
- Alocação: N / D
- Modelo Intervencional: Atribuição de grupo único
- Mascaramento: Nenhum (rótulo aberto)
Armas e Intervenções
Grupo de Participantes / Braço |
Intervenção / Tratamento |
---|---|
Experimental: Technolas 217z Excimer Laser
Bausch & Lomb Zyoptix Aspheric Algorithm for LASIK correction of myopia and myopic astigmatism.
|
LASIK correction of myopia and myopic astigmatism
|
O que o estudo está medindo?
Medidas de resultados primários
Medida de resultado |
Descrição da medida |
Prazo |
---|---|---|
Percentage of Eyes With Uncorrected High Contrast Distance Visual Acuity of 20/40 or Better
Prazo: 3 months
|
3 months
|
|
Percentage of Eyes With Manifest Subjective Refraction (MRSE) Within ± 1.00 Diopter (D) and 0.50 D of Emmetropia
Prazo: 3 months
|
Manifest refractions (eyeglass prescriptions) have three components: sphere, cylinder, and axis.
Sphere and cylinder are both expressed in diopters, which is a continuous measure of the focusing power needed to make the image sharp on the retina.
Manifest refraction spherical equivalent (MRSE) is equal to sphere + ½ x cylinder.
It is expressed in diopters (D).
|
3 months
|
Preservation of Manifest Best Corrected High Contrast Distance Visual Acuity
Prazo: Baseline, 3 months
|
Mean change in best-corrected high contrast distance visual acuity.
Corrected means spectacle corrected.
Visual acuity (VA) was reported as letters read correctly, and the letters read were converted to logarithm of the minimum angle of resolution (logMAR) acuity.
The participant read rows of letters on a standard LogMAR chart until the participant misses 3 letters on a row with 5 letters.
The total number of correct letters were recorded.
A decrease in the number of correct letters indicates a decrease in visual acuity.
Acuity was averaged across visits.
|
Baseline, 3 months
|
Percentage of Eyes With Manifest Best-corrected Distance Photopic Visual Acuity Decrease of 2 or More Lines
Prazo: 3 months
|
3 months
|
|
Percentage of Eyes With > 2.00 Diopter of Induced Postoperative Refractive Cylinder
Prazo: 3 months
|
Manifest refractions (eyeglass prescriptions) have three components: sphere, cylinder, and axis.
Sphere and cylinder are both expressed in diopters, which is a continuous measure of the focusing power needed to make the image sharp on the retina.
Manifest refraction spherical equivalent (MRSE) is equal to sphere + ½ x cylinder.
It is expressed in diopters (D).
|
3 months
|
Percentage of Eyes That Had High Contrast Best Spectacle Corrected Visual Acuity (HCBSCVA) of 20/20 or Better at Baseline Had a Visual Outcome Worse Than 20/40 at 3 Months
Prazo: 3 months
|
Corrected means spectacle corrected.
Visual acuity (VA) was reported as letters read correctly, and the letters read were converted to logarithm of the minimum angle of resolution (logMAR) acuity.
The participant read rows of letters on a standard LogMAR chart until the participant misses 3 letters on a row with 5 letters.
The total number of correct letters were recorded.
A decrease in the number of correct letters indicates a decrease in visual acuity.
Acuity was averaged across visits.
|
3 months
|
Medidas de resultados secundários
Medida de resultado |
Descrição da medida |
Prazo |
---|---|---|
Percentage Change From Baseline in Higher Order Aberrations.
Prazo: Baseline, 3 months
|
The aberrations in the eye's optical system were measured over the entire pupil by the Bausch & Lomb Zywave II WaveFront Aberrometer, a Hartmann-Shack type device.
The pupil should have been at least 6 mm in diameter using 2.5% phenylephrine as a dilating agent to maximize the pupil diameter and hence the amount of wavefront information collected by the Zywave II.
The wavefront data was then fitted with Zernike polynomials representing the 2nd, 3rd, 4th and 5th order Zernike terms.
These terms represent the wavefront aberration of the eye.
|
Baseline, 3 months
|
Colaboradores e Investigadores
É aqui que você encontrará pessoas e organizações envolvidas com este estudo.
Patrocinador
Investigadores
- Investigador principal: Mark Cohen, MD, Lasik MD
Datas de registro do estudo
Essas datas acompanham o progresso do registro do estudo e os envios de resumo dos resultados para ClinicalTrials.gov. Os registros do estudo e os resultados relatados são revisados pela National Library of Medicine (NLM) para garantir que atendam aos padrões específicos de controle de qualidade antes de serem publicados no site público.
Datas Principais do Estudo
Início do estudo
1 de agosto de 2008
Conclusão Primária (Real)
1 de março de 2010
Conclusão do estudo (Real)
1 de março de 2010
Datas de inscrição no estudo
Enviado pela primeira vez
8 de outubro de 2008
Enviado pela primeira vez que atendeu aos critérios de CQ
8 de outubro de 2008
Primeira postagem (Estimativa)
9 de outubro de 2008
Atualizações de registro de estudo
Última Atualização Postada (Real)
11 de setembro de 2020
Última atualização enviada que atendeu aos critérios de controle de qualidade
24 de agosto de 2020
Última verificação
1 de agosto de 2020
Mais Informações
Termos relacionados a este estudo
Termos MeSH relevantes adicionais
Outros números de identificação do estudo
- 564
Essas informações foram obtidas diretamente do site clinicaltrials.gov sem nenhuma alteração. Se você tiver alguma solicitação para alterar, remover ou atualizar os detalhes do seu estudo, entre em contato com register@clinicaltrials.gov. Assim que uma alteração for implementada em clinicaltrials.gov, ela também será atualizada automaticamente em nosso site .
Ensaios clínicos em Bausch & Lomb 217z Excimer Laser
-
The S.N. Fyodorov Eye Microsurgery State InstitutionDesconhecidoDescolamento da retinaFederação Russa
-
Bausch & Lomb IncorporatedConcluído
-
University of WaterlooAlcon ResearchConcluído
-
Johnson & Johnson Vision Care, Inc.ConcluídoAcuidade visualEstados Unidos
-
Bausch & Lomb IncorporatedRetiradoAstigmatismo | Miopia
-
Bausch Health Americas, Inc.ConcluídoMiopiaEstados Unidos
-
Bausch & Lomb IncorporatedConcluídoAstigmatismo | HipermetropiaEstados Unidos
-
Bausch & Lomb IncorporatedConcluído
-
Bausch & Lomb IncorporatedConcluídoCatarata | AphakiaAlemanha
-
Vastra Gotaland RegionConcluídoInflamação | Uveíte | Catarata | Opacificação da Cápsula PosteriorSuécia